NCT03461952View on ClinicalTrials.gov

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

February 9, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

Nivolumab

240mg

DRUG

Ipilimumab

1mg/kg

Trial Locations (6)

10032

Columbia University Medical Center, New York

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Cancer Research Institute, New York City

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Personal Genome Diagnostics

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK